Login Preferences
About News Publications Statistics Downloads API Guide License How to use Preferences
bn:00233023n
Noun Concept
Categories: Gastroenterology, Drugboxes which contain changes to watched fields, Anti-inflammatory agents, AbbVie Inc. brands, Takeda Pharmaceutical Company brands
EN
mesalazine  5-Amino-2-hydroxybenzoic acid  3-carboxy-4-hydroxyaniline  5-Aminosalicylate  5-aminosalicylic acid
EN
Mesalazine, also known as mesalamine or 5-aminosalicylic acid, is a medication used to treat inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Wikipedia
Definitions
Relations
Sources
EN
Mesalazine, also known as mesalamine or 5-aminosalicylic acid, is a medication used to treat inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Wikipedia
Chemical compound Wikidata
IS A
compound
medicine
MEDICAL CONDITION TREATED
colitis
irritable bowel syndrome
proctitis
ulcerative colitis
microscopic colitis
SUBJECT HAS ROLE
nonsteroidal anti-inflammatory
Arachidonate 5-lipoxygenase inhibitor
cyclooxygenase inhibitors
Wikipedia
EN
mesalazine
Wikidata
EN
mesalazine
Wikipedia Redirections
EN
5-amino-2-hydroxybenzoic acid, 5-Amino-2-hydroxybenzoic acid, 5-aminosalicylate, 5-aminosalicylic acid, 5-ASA, 5ASA, Apriso, Asacol, Asacol HD, Asacolitin, ATC code A07EC02, ATCvet code QA07EC02, Azachol, Canasa, Celafalc, Celafalk, Celofalc, Celofalk, Claversal, Delzicol, Fisalamine, Lialda, Lixacol, mesalamine, Mesasal, Meslamine, Mezavant, Mezera, Octasa, Pentasa, Pentasa granules, Pentasax, Rowasa, Salefalk, Salofalk, Sfrowasa, Yaldigo, Zintasa
Wikidata Alias
EN
3-carboxy-4-hydroxyaniline, 5-Aminosalicylate, 5-aminosalicylic acid, 5-ASA, m-Aminosalicylic acid, Mesalamine, Mesalazina, Mesalazine, Mesalazinum, Mésalazine, p-Aminosalicylsaeure, Pentasa®

Please note that, in order to improve your browsing experience on this website, BabelNet® uses various types of cookies, including: browsing functionality, performance and statistical cookies.

By continuing to browse the site you are agreeing to our use of cookies. OK

License